|Bid||0.0000 x 3200|
|Ask||0.0000 x 1800|
|Day's Range||2.7400 - 2.8800|
|52 Week Range||1.3500 - 4.7650|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors can't complain about Agile Therapeutics' (NASDAQ: AGRX) stock performance so far this year. Agile Therapeutics doesn't have an approved product on the market yet. Agile announced Q3 total operating expenses of $14.7 million, a 227% jump from the $4.5 million reported in the prior-year period.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.